Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA

9 September 2026 · By · Wire by Fusion42

Published

9 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at biospace.com →

◆ Verified

Fusion42 · 9 September 2026 · Fusion42 review

InnoCare Pharma received approval from China's National Medical Products Administration to start clinical trials for ICP-B381, a novel bispecific antibody-drug conjugate targeting PSMA and STEAP1 for solid tumors including prostate cancer.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new competitor moving into bispecific ADCs for prostate cancer in China. This opens a door to explore PSMA/STEAP1 targeting opportunities or consider partnerships given the innovative ADC design just entering clinical tests.

◆ Coverage

1 source · 9 Sep 2026

◆ Related on Wire

◆ Topics

Biotechbispecific-adcclinical-trialprostate-cancerchinadrug-approval